Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Oramed Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer ... Officer, Mr. Nadav,Kidron, will be giving a company presentation ... New York City,s Palace Hotel on November,11. Mr. Kidron ... the Kennedy II,Ballroom, located on the 4th floor of ...
... Oct. 30 STERIS Corporation,(NYSE: STE ) today ... September 30, 2008. Fiscal 2009 second quarter revenues,increased 10% ... second,quarter of fiscal 2008, driven by strong growth in ... was $28.8 million, or $0.48,per diluted share, compared with ...
... DNA and Fingerprint portraits go global by incorporating cutting-edge localization technology online ... , ... New York, NY (PRWEB) October 30, 2008 -- DNA 11, ... and fingerprints, mark global growth with the launch of a new website ...
Cached Biology Technology:Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC) 2STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 2STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 3STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 4STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 5STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 6STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 7STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 8STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 9STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 10STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 11DNA 11, Creators of DNA Art Goes Global 2
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... New Rochelle, NY, June 28, 2013 Mary Ann Liebert, ... Printing and Additive Manufacturing , a highly innovative, peer-reviewed ... issue will publish in the fall of 2013, and ... the Director of Cornell University,s Creative Machines Lab at ...
... The world,s food supply got a little more plentiful thanks ... plant pathology at Kansas State University, and his colleague, Jorge ... that identified a gene that gives wheat plants resistance to ... rust pathogen -- called Ug99 -- that was first discovered ...
... 28 2013) A study carried out in India examining ... marrow stem cells in patients with type 2 diabetes ... compared to a control group of TD2M patients who ... The study appears as an early e-publication for the ...
Cached Biology News:Resistance gene found against Ug99 wheat stem rust pathogen 2Resistance gene found against Ug99 wheat stem rust pathogen 3Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2
100 ug affinity purified rabbit anti-JIP-1 polyclonal antibody. Reacts with mouse and rat. Perform well in Western blotting. Other applications have not been tested. Storage Temperature: -20C Shi...
Epstein-Barr Virus (EBV) (EBNA-1)...
XBP-1 (F-4)...
X box-binding protein 1...
Biology Products: